Short answer
Cardiff Oncology, Inc. (CRDF) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $120,000 (down 26.8% year over year) with net income of −$11M.
Q3 2025 key financials · XBRL
- Revenue
- $120,000
- −26.8% YoY · −0.8% QoQ
- Net income
- −$11M
- +5.0% YoY · +19.3% QoQ
- Operating margin
- -9978.3%
- EPS (diluted)
- −$0.17
- +32.0% YoY · +19.0% QoQ
Source: XBRL data from the Cardiff Oncology, Inc. (CRDF) Q3 2025 10-Q on SEC EDGAR. USD.
Cardiff Oncology, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added FDA, SEC funding risk: Inadequate appropriations could impair hiring and agency operations
- Most material update: Government shutdowns could delay regulatory reviews and restrict public-market capital access
- Regulatory risk: FDA review times fluctuate with staffing, funding, user fees, and policy changes
- Operational risk: Prolonged shutdowns or global health concerns could halt inspections and regulatory activities
- Financial risk: Agency disruptions could impair access to necessary capital for continued operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cardiff Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.